Sweden
Empe Diagnostics is a Swedish biotech company founded in 2015 that focuses on precision diagnostics for tuberculosis (MDR/XDR-TB) with the slogan "Confirmatory precision diagnostics for tuberculosis (MDR/XDR-TB) within 3 h even at resource-limited labs." With 10 million new cases of Tuberculosis (TB) reported annually and 4000 daily fatalities, rapid and accurate detection is crucial. Empe Diagnostics has developed the mfloDx® technology, capable of detecting TB-causing bacteria and drug-resistance profiles in under 3 hours directly from patient samples. This technology has tremendous potential, not only for TB but also for other RNA/DNA transcript-related diseases, with plans to expand the product portfolio to include sexually transmitted diseases.
Having received a kr23.76M Series A investment on 07 April 2020 from Sciety, Empe Diagnostics is making significant strides. Their first product, miniMDR-TB, for research purposes, is already released, and the second flagship product is prepared for a research release. Overall, Empe Diagnostics is addressing a critical global health issue and has demonstrated impressive progress and potential for growth.
